Cytomegalovirus infection after liver transplantation

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Key Points 1. Cytomegalovirus (CMV) is a common infection after liver transplantation and manifests as an asymptomatic infection or clinically as CMV syndrome (fever and myelosuppression) or tissue-invasive CMV disease. 2. The most common risk factor for CMV disease is donor positivity and recipient negativity for CMV, and severe impairment in immunity, especially with a pathogen-specific immune response, generally predisposes patients to CMV disease after transplantation. 3. The prevention of CMV disease after liver transplantation consists of preemptive therapy (antiviral therapy is administered only in the presence of a positive CMV polymerase chain reaction or pp65 antigenemia) or antiviral prophylaxis (an antiviral drug is administered to all patients at risk of CMV disease). 4. The treatment of CMV disease consists of intravenous ganciclovir (for severe disease) or oral valganciclovir (for mild to moderate CMV disease). Liver Transpl 16:S45-S53, 2010. copy; 2009 AASLD.

Original languageEnglish (US)
JournalLiver Transplantation
Volume16
Issue numberSUPPL. 2
DOIs
StatePublished - Oct 2010
Externally publishedYes

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Liver Transplantation
Antiviral Agents
Ganciclovir
Asymptomatic Infections
Immunity
Fever
Therapeutics
Transplantation
Tissue Donors
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Hepatology
  • Surgery
  • Transplantation

Cite this

Cytomegalovirus infection after liver transplantation. / Razonable, Raymund R.

In: Liver Transplantation, Vol. 16, No. SUPPL. 2, 10.2010.

Research output: Contribution to journalArticle

@article{1be3f5708d17423c8b3cba9d3981222f,
title = "Cytomegalovirus infection after liver transplantation",
abstract = "Key Points 1. Cytomegalovirus (CMV) is a common infection after liver transplantation and manifests as an asymptomatic infection or clinically as CMV syndrome (fever and myelosuppression) or tissue-invasive CMV disease. 2. The most common risk factor for CMV disease is donor positivity and recipient negativity for CMV, and severe impairment in immunity, especially with a pathogen-specific immune response, generally predisposes patients to CMV disease after transplantation. 3. The prevention of CMV disease after liver transplantation consists of preemptive therapy (antiviral therapy is administered only in the presence of a positive CMV polymerase chain reaction or pp65 antigenemia) or antiviral prophylaxis (an antiviral drug is administered to all patients at risk of CMV disease). 4. The treatment of CMV disease consists of intravenous ganciclovir (for severe disease) or oral valganciclovir (for mild to moderate CMV disease). Liver Transpl 16:S45-S53, 2010. copy; 2009 AASLD.",
author = "Razonable, {Raymund R}",
year = "2010",
month = "10",
doi = "10.1002/lt.22144",
language = "English (US)",
volume = "16",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Cytomegalovirus infection after liver transplantation

AU - Razonable, Raymund R

PY - 2010/10

Y1 - 2010/10

N2 - Key Points 1. Cytomegalovirus (CMV) is a common infection after liver transplantation and manifests as an asymptomatic infection or clinically as CMV syndrome (fever and myelosuppression) or tissue-invasive CMV disease. 2. The most common risk factor for CMV disease is donor positivity and recipient negativity for CMV, and severe impairment in immunity, especially with a pathogen-specific immune response, generally predisposes patients to CMV disease after transplantation. 3. The prevention of CMV disease after liver transplantation consists of preemptive therapy (antiviral therapy is administered only in the presence of a positive CMV polymerase chain reaction or pp65 antigenemia) or antiviral prophylaxis (an antiviral drug is administered to all patients at risk of CMV disease). 4. The treatment of CMV disease consists of intravenous ganciclovir (for severe disease) or oral valganciclovir (for mild to moderate CMV disease). Liver Transpl 16:S45-S53, 2010. copy; 2009 AASLD.

AB - Key Points 1. Cytomegalovirus (CMV) is a common infection after liver transplantation and manifests as an asymptomatic infection or clinically as CMV syndrome (fever and myelosuppression) or tissue-invasive CMV disease. 2. The most common risk factor for CMV disease is donor positivity and recipient negativity for CMV, and severe impairment in immunity, especially with a pathogen-specific immune response, generally predisposes patients to CMV disease after transplantation. 3. The prevention of CMV disease after liver transplantation consists of preemptive therapy (antiviral therapy is administered only in the presence of a positive CMV polymerase chain reaction or pp65 antigenemia) or antiviral prophylaxis (an antiviral drug is administered to all patients at risk of CMV disease). 4. The treatment of CMV disease consists of intravenous ganciclovir (for severe disease) or oral valganciclovir (for mild to moderate CMV disease). Liver Transpl 16:S45-S53, 2010. copy; 2009 AASLD.

UR - http://www.scopus.com/inward/record.url?scp=78651400499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651400499&partnerID=8YFLogxK

U2 - 10.1002/lt.22144

DO - 10.1002/lt.22144

M3 - Article

AN - SCOPUS:78651400499

VL - 16

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - SUPPL. 2

ER -